ABSTRACT
The clinical course of multiple sclerosis (MS) is highly variable, and the pathological changes that are seen with the disease are heterogeneous amongst individuals. In recent years, there has been increasing interest in the development of magnetic resonance imaging (MRI) approaches to characterize the pathological substrates of disability in MS1 in the hope that quantitative in vivo indices of pathology could provide new insights into the pathogenesis of the disease, as well as provide more specific and sensitive end-points for treatment trials.
